Published in Clin Microbiol Infect on May 01, 2006
Setting and revising antibacterial susceptibility breakpoints. Clin Microbiol Rev (2007) 3.18
Progress in antifungal susceptibility testing of Candida spp. by use of Clinical and Laboratory Standards Institute broth microdilution methods, 2010 to 2012. J Clin Microbiol (2012) 2.82
Wild-type MIC distributions and epidemiological cutoff values for the echinocandins and Candida spp. J Clin Microbiol (2009) 2.47
Wild-type MIC distributions and epidemiological cutoff values for the triazoles and six Aspergillus spp. for the CLSI broth microdilution method (M38-A2 document). J Clin Microbiol (2010) 2.19
Interlaboratory variability of Caspofungin MICs for Candida spp. Using CLSI and EUCAST methods: should the clinical laboratory be testing this agent? Antimicrob Agents Chemother (2013) 2.14
Low prevalence of fks1 hot spot 1 mutations in a worldwide collection of Candida strains. Antimicrob Agents Chemother (2010) 2.03
Wild-type MIC distribution and epidemiological cutoff values for Aspergillus fumigatus and three triazoles as determined by the Clinical and Laboratory Standards Institute broth microdilution methods. J Clin Microbiol (2009) 1.99
Antimicrobial resistance in Haemophilus influenzae. Clin Microbiol Rev (2007) 1.74
Comparison of European Committee on Antimicrobial Susceptibility Testing (EUCAST) and Etest methods with the CLSI broth microdilution method for echinocandin susceptibility testing of Candida species. J Clin Microbiol (2010) 1.68
Wild-type MIC distributions and epidemiological cutoff values for amphotericin B and Aspergillus spp. for the CLSI broth microdilution method (M38-A2 document). Antimicrob Agents Chemother (2011) 1.59
Current perspectives on echinocandin class drugs. Future Microbiol (2011) 1.44
Use of epidemiological cutoff values to examine 9-year trends in susceptibility of Aspergillus species to the triazoles. J Clin Microbiol (2010) 1.39
Wild-type MIC distributions and epidemiological cutoff values for caspofungin and Aspergillus spp. for the CLSI broth microdilution method (M38-A2 document). Antimicrob Agents Chemother (2011) 1.30
Frequency of fks mutations among Candida glabrata isolates from a 10-year global collection of bloodstream infection isolates. Antimicrob Agents Chemother (2013) 1.29
Triazole and echinocandin MIC distributions with epidemiological cutoff values for differentiation of wild-type strains from non-wild-type strains of six uncommon species of Candida. J Clin Microbiol (2011) 1.29
Cryptococcus neoformans-Cryptococcus gattii species complex: an international study of wild-type susceptibility endpoint distributions and epidemiological cutoff values for fluconazole, itraconazole, posaconazole, and voriconazole. Antimicrob Agents Chemother (2012) 1.28
Wild-type MIC distributions and epidemiological cutoff values for amphotericin B, flucytosine, and itraconazole and Candida spp. as determined by CLSI broth microdilution. J Clin Microbiol (2012) 1.27
Use of epidemiological cutoff values to examine 9-year trends in susceptibility of Candida species to anidulafungin, caspofungin, and micafungin. J Clin Microbiol (2010) 1.26
Antimicrobial susceptibilities of commonly encountered bacterial isolates to fosfomycin determined by agar dilution and disk diffusion methods. Antimicrob Agents Chemother (2011) 1.25
Wild-type MIC distributions and epidemiological cutoff values for posaconazole and voriconazole and Candida spp. as determined by 24-hour CLSI broth microdilution. J Clin Microbiol (2010) 1.22
Multicenter study of isavuconazole MIC distributions and epidemiological cutoff values for Aspergillus spp. for the CLSI M38-A2 broth microdilution method. Antimicrob Agents Chemother (2013) 1.20
Multilaboratory study of epidemiological cutoff values for detection of resistance in eight Candida species to fluconazole, posaconazole, and voriconazole. Antimicrob Agents Chemother (2014) 1.13
Comparison of three statistical methods for establishing tentative wild-type population and epidemiological cutoff values for echinocandins, amphotericin B, flucytosine, and six Candida species as determined by the colorimetric Sensititre YeastOne method. J Clin Microbiol (2012) 1.12
Echinocandin resistance, susceptibility testing and prophylaxis: implications for patient management. Drugs (2014) 1.10
Epidemiological cutoff values for azoles and Aspergillus fumigatus based on a novel mathematical approach incorporating cyp51A sequence analysis. Antimicrob Agents Chemother (2012) 1.09
Antimicrobial Susceptibilities of Abiotrophia defectiva, Granulicatella adiacens, and Granulicatella elegans. Antimicrob Agents Chemother (2015) 1.06
The intrinsic resistome of bacterial pathogens. Front Microbiol (2013) 1.05
Cryptococcus neoformans-Cryptococcus gattii species complex: an international study of wild-type susceptibility endpoint distributions and epidemiological cutoff values for amphotericin B and flucytosine. Antimicrob Agents Chemother (2012) 1.02
Normalized resistance interpretation as a tool for establishing epidemiological MIC susceptibility breakpoints. J Clin Microbiol (2010) 1.02
Multicenter Study of Epidemiological Cutoff Values and Detection of Resistance in Candida spp. to Anidulafungin, Caspofungin, and Micafungin Using the Sensititre YeastOne Colorimetric Method. Antimicrob Agents Chemother (2015) 0.99
Multicenter study of anidulafungin and micafungin MIC distributions and epidemiological cutoff values for eight Candida species and the CLSI M27-A3 broth microdilution method. Antimicrob Agents Chemother (2013) 0.96
International Evaluation of MIC Distributions and Epidemiological Cutoff Value (ECV) Definitions for Fusarium Species Identified by Molecular Methods for the CLSI Broth Microdilution Method. Antimicrob Agents Chemother (2015) 0.92
Epidemiological cutoff values for fluconazole, itraconazole, posaconazole, and voriconazole for six Candida species as determined by the colorimetric Sensititre YeastOne method. J Clin Microbiol (2013) 0.91
Household risk factors for colonization with multidrug-resistant Staphylococcus aureus isolates. PLoS One (2013) 0.89
The use of machine learning methodologies to analyse antibiotic and biocide susceptibility in Staphylococcus aureus. PLoS One (2013) 0.89
Investigating antibiotic resistance in non-clinical environments. Front Microbiol (2013) 0.88
Validation of antibiotic susceptibility testing guidelines in a routine clinical microbiology laboratory exemplifies general key challenges in setting clinical breakpoints. Antimicrob Agents Chemother (2014) 0.87
Multicenter evaluation of MIC distributions for epidemiologic cutoff value definition to detect amphotericin B, posaconazole, and itraconazole resistance among the most clinically relevant species of Mucorales. Antimicrob Agents Chemother (2015) 0.86
Integrating forecast probabilities in antibiograms: a way to guide antimicrobial prescriptions more reliably? J Clin Microbiol (2014) 0.85
Multicenter study of isavuconazole MIC distributions and epidemiological cutoff values for the Cryptococcus neoformans-Cryptococcus gattii species complex using the CLSI M27-A3 broth microdilution method. Antimicrob Agents Chemother (2014) 0.85
Gyrase Mutations Are Associated with Variable Levels of Fluoroquinolone Resistance in Mycobacterium tuberculosis. J Clin Microbiol (2016) 0.84
Pharmacodynamics of doxycycline and tetracycline against Staphylococcus pseudintermedius: proposal of canine-specific breakpoints for doxycycline. J Clin Microbiol (2013) 0.84
A statistical approach for determination of disk diffusion-based cutoff values for systematic characterization of wild-type and non-wild-type bacterial populations in antimicrobial susceptibility testing. J Clin Microbiol (2015) 0.82
Defining antibiotic resistance-towards international harmonization. Ups J Med Sci (2014) 0.81
Use of in vitro vancomycin testing results to predict susceptibility to oritavancin, a new long-acting lipoglycopeptide. Antimicrob Agents Chemother (2015) 0.81
Effect of dosing and dosing frequency on the efficacy of ceftizoxime and the emergence of ceftizoxime resistance during the early development of murine abscesses caused by Bacteroides fragilis and Enterobacter cloacae mixed infection. Antimicrob Agents Chemother (2007) 0.80
Multicenter and international study of MIC/MEC distributions for definition of epidemiological cutoff values (ECVs) for species of Sporothrix identified by molecular methods. Antimicrob Agents Chemother (2017) 0.79
Minimal inhibitory concentration distributions and epidemiological cutoff values of five antifungal agents against Sporothrix brasiliensis. Mem Inst Oswaldo Cruz (2017) 0.79
Determination of MIC distribution and epidemiological cutoff values for bedaquiline and delamanid in Mycobacterium tuberculosis using the MGIT 960 system equipped with TB eXiST. Antimicrob Agents Chemother (2015) 0.78
The Resistant-Population Cutoff (RCOFF): a New Concept for Improved Characterization of Antimicrobial Susceptibility Patterns of Non-Wild-Type Bacterial Populations. J Clin Microbiol (2015) 0.77
A multi-center study of method-dependent epidemiological cutoff values (ECVs) for resistance detection in Candida spp. and Aspergillus spp. to amphotericin B and echinocandins for the Etest agar diffusion method. Antimicrob Agents Chemother (2016) 0.77
Predictability of Phenotype in Relation to Common β-Lactam Resistance Mechanisms in Escherichia coli and Klebsiella pneumoniae. J Clin Microbiol (2016) 0.76
Development of a disk diffusion method for testing Moraxella catarrhalis susceptibility using clinical and laboratory standards institute methods: a SENTRY antimicrobial surveillance program report. J Clin Microbiol (2009) 0.75
Susceptibility breakpoint for enrofloxacin against swine Salmonella spp. J Clin Microbiol (2013) 0.75
In vitro antifungal susceptibility testing of Candida isolates with the EUCAST methodology. Antimicrob Agents Chemother (2017) 0.75
Aeromonas Diversity and Antimicrobial Susceptibility in Freshwater-An Attempt to Set Generic Epidemiological Cut-Off Values. Front Microbiol (2017) 0.75
The Epidemiologic and Pharmacodynamic Cutoff Values of Tilmicosin against Haemophilus parasuis. Front Microbiol (2016) 0.75
Geometric least squares means ratios for the analysis of Plasmodium falciparum in vitro susceptibility to antimalarial drugs. Malar J (2007) 0.75
Patterns of antimicrobial resistance in Streptococcus suis isolates from pigs with or without streptococcal disease in England between 2009 and 2014. Vet Microbiol (2017) 0.75
Monitoring Antifungal Resistance in a Global Collection of Invasive Yeasts and Moulds: Application of CLSI Epidemiological Cutoff Values and Whole Genome Sequencing Analysis for Detection of Azole Resistance in Candida albicans. Antimicrob Agents Chemother (2017) 0.75
Molecular Characterization of Reduced Susceptibility to Biocides in Clinical Isolates of Acinetobacter baumannii. Front Microbiol (2017) 0.75
Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect (2011) 17.47
A rapid slide-agglutination method for typing pneumococci by means of specific antibody adsorbed to protein A-containing staphylococci. J Med Microbiol (1973) 10.31
New method for the serological grouping of Streptococci with specific antibodies adsorbed to protein A-containing staphylococci. Infect Immun (1973) 7.92
Differences in anti-protein A activity among IgG subgroups. J Immunol (1969) 4.56
Slide agglutination method for the serological identification of Neisseria gonorrhoeae with anti-gonococcal antibodies adsorbed to protein A-containing staphylococci. Appl Microbiol (1974) 4.17
Phylogenetic insight into evolution of mammalian Fc fragment of gamma G globulin using staphylococcal protein A. J Immunol (1970) 3.84
Purification and some properties of streptococcal protein G, a novel IgG-binding reagent. J Immunol (1984) 3.56
A surface component in group A, C, and G streptococci with non-immune reactivity for immunoglobulin G. J Immunol (1973) 3.23
Effect of clonal and serotype-specific properties on the invasive capacity of Streptococcus pneumoniae. J Infect Dis (2004) 3.14
Differential staining of bacteria in clinical specimens using acridine orange buffered at low pH. Acta Pathol Microbiol Scand B (1977) 2.94
A rountine diagnostic test for IgA and IgM antibodies to rubella virus: absorption of IgG with Staphylococcus aureus. J Infect Dis (1974) 2.67
EUCAST expert rules in antimicrobial susceptibility testing. Clin Microbiol Infect (2011) 2.65
Definition of staphylococcal protein A reactivity for human immunoglobulin G fragments. Immunochemistry (1970) 2.61
Antiphagocytic effects of staphylococcal protein A. J Immunol (1969) 2.59
Protein A reactivity with mouse immunoglobulins. Structural relationship between some mouse and human immunoglobulins. J Immunol (1970) 2.38
Characterization and nucleotide sequence of a Klebsiella oxytoca cryptic plasmid encoding a CMY-type beta-lactamase: confirmation that the plasmid-mediated cephamycinase originated from the Citrobacter freundii AmpC beta-lactamase. Antimicrob Agents Chemother (1999) 2.27
Antibody response in rabbits to immunization with Mycobacterium leprae. Infect Immun (1977) 2.21
Aminoglycoside toxicity - a review of clinical studies published between 1975 and 1982. J Antimicrob Chemother (1984) 2.21
The use of protein A-containing Staphylococcus aureus as a solid phase anti-IgG reagent in radioimmunoassays as exemplified in the quantitation of alpha-fetoprotein in normal human adult serum. Eur J Immunol (1974) 2.19
Quantitation of staphylococcal protein A: Determination of equilibrium constant and number of protein A residues on bacteria. J Immunol (1970) 2.19
Heterogeneity of nonimmune immunoglobulin Fc reactivity among gram-positive cocci: description of three major types of receptors for human immunoglobulin G. Infect Immun (1977) 2.15
ESCMID guidelines for the management of the infection control measures to reduce transmission of multidrug-resistant Gram-negative bacteria in hospitalized patients. Clin Microbiol Infect (2014) 2.13
Lymphocyte transformation test in leprosy; correlation of the response with inflammation of lesions. Clin Exp Immunol (1976) 2.08
European recommendations for antimicrobial resistance surveillance. Clin Microbiol Infect (2004) 1.95
Specific absorption of human serum albumin, immunoglobulin A, and immunoglobulin G with selected strains of group A and G streptococci. Infect Immun (1979) 1.92
Evaluation of a cefoxitin 30 microg disc on Iso-Sensitest agar for detection of methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother (2003) 1.91
Proposed mechanism for metronidazole resistance in Helicobacter pylori. J Antimicrob Chemother (1992) 1.90
Lipoteichoic acid is the major cell wall component responsible for surface hydrophobicity of group A streptococci. Infect Immun (1983) 1.89
Preliminary taxonomic studies on the leprosy bacillus. Br J Exp Pathol (1975) 1.83
Antibiotic medication and bacterial resistance to antibiotics: a survey of children in a Vietnamese community. Trop Med Int Health (2000) 1.72
Fibrinogen binding structures in beta-hemolytic streptococci group A, C, and G. Comparisons with receptors for IgG and aggregated beta 2-microglobulin. Acta Pathol Microbiol Scand B (1979) 1.70
Cross-reactions between mycobacteria. II. Crossed immunoelectrophoretic analysis of soluble antigens of BCG and comparison with other mycobacteria. Scand J Immunol (1979) 1.67
Immune complexes and complement hypercatabolism in patients with leprosy. Clin Exp Immunol (1976) 1.66
Development of the EUCAST disk diffusion antimicrobial susceptibility testing method and its implementation in routine microbiology laboratories. Clin Microbiol Infect (2013) 1.65
Mycobacterium leprae specific antibodies detected by radioimmunoassay. Scand J Immunol (1978) 1.61
Studies of mycobacterial antigens, with special reference to Mycobacterium leprae. Infect Immun (1976) 1.55
The role of pharmacokinetics/pharmacodynamics in setting clinical MIC breakpoints: the EUCAST approach. Clin Microbiol Infect (2012) 1.53
Binding of aggregated human beta2-microglobulin to surface protein structure in group A, C, and G streptococci. Infect Immun (1978) 1.53
Little evidence for reversibility of trimethoprim resistance after a drastic reduction in trimethoprim use. J Antimicrob Chemother (2009) 1.51
The E test for antimicrobial susceptibility testing of Helicobacter pylori. J Antimicrob Chemother (1993) 1.50
Staphylococcus lugdunensis in several niches of the normal skin flora. Clin Microbiol Infect (2009) 1.50
Genetic basis of resistance to fusidic acid in staphylococci. Antimicrob Agents Chemother (2007) 1.48
Demonstration of specific binding sites for human serum albumin in group C and G streptococci. Infect Immun (1980) 1.46
Norfloxacin treatment of salmonellosis does not shorten the carrier stage. Scand J Infect Dis (1990) 1.46
Integrons and gene cassettes in clinical isolates of co-trimoxazole-resistant Gram-negative bacteria. Clin Microbiol Infect (2005) 1.39
Escherichia coli and Staphylococcus aureus: bad news and good news from the European Antimicrobial Resistance Surveillance Network (EARS-Net, formerly EARSS), 2002 to 2009. Euro Surveill (2011) 1.34
Wild-type MIC distributions of four fluoroquinolones active against Mycobacterium tuberculosis in relation to current critical concentrations and available pharmacokinetic and pharmacodynamic data. J Antimicrob Chemother (2010) 1.34
Phenotypic detection of methicillin resistance in Staphylococcus aureus by disk diffusion testing and Etest on Mueller-Hinton agar. J Clin Microbiol (2006) 1.33
Receptors for human plasminogen on gram-negative bacteria. Infect Immun (1990) 1.33
Methods for identifying methicillin resistancein Staphylococcus aureus. J Hosp Infect (2001) 1.32
Evaluation of three commercial enzyme-linked immunosorbent assays and two latex agglutination assays for diagnosis of primary Epstein-Barr virus infection. J Clin Microbiol (1997) 1.28
Evaluation of cefoxitin 5 and 10 microg discs for the detection of methicillin resistance in staphylococci. J Antimicrob Chemother (2005) 1.28
Invasive disease caused by Haemophilus influenzae in Sweden 1997-2009; evidence of increasing incidence and clinical burden of non-type b strains. Clin Microbiol Infect (2011) 1.27
Activation and inhibition of IgG mediated complement fixation by staphylococcal protein A. Clin Exp Immunol (1970) 1.27
Evaluation of four selective agars and two enrichment broths in screening for methicillin-resistant Staphylococcus aureus. J Clin Microbiol (2008) 1.26
Wild-type MIC distributions for aminoglycoside and cyclic polypeptide antibiotics used for treatment of Mycobacterium tuberculosis infections. J Clin Microbiol (2010) 1.24
Mycobacterial antigens in antibody responses of leprosy patients. Int J Lepr Other Mycobact Dis (1976) 1.23
Tissue-type plasminogen activator-mediated activation of plasminogen on the surface of group A, C, and G streptococci. Infect Immun (1992) 1.23
Clonal spread among Swedish children of a Staphylococcus aureus strain resistant to fusidic acid. Scand J Infect Dis (2002) 1.19
Antigenic heterogeneity in patients with reactions in borderline leprosy. Br Med J (1975) 1.18
Letter: Prolonged excretion of gentamicin in a patient with umimpaired renal function. Lancet (1975) 1.16
Antimicrobial susceptibility testing in Sweden. II. Species-related zone diameter breakpoints to avoid interpretive errors and guard against unrecognized evolution of resistance. Scand J Infect Dis Suppl (1997) 1.16
Extended spectrum beta-lactamase from Klebsiella oxytoca, not belonging to the TEM or SHV family. J Antimicrob Chemother (1992) 1.15
A new method for normalized interpretation of antimicrobial resistance from disk test results for comparative purposes. Clin Microbiol Infect (2003) 1.15
Reactions between certain strains of pneumococci and Fc of IgG. J Immunol (1974) 1.14
Additive effect of clarithromycin combined with 14-hydroxy clarithromycin, erythromycin, amoxycillin, metronidazole or omeprazole against Helicobacter pylori. J Antimicrob Chemother (1994) 1.13
Hospital-acquired infections among surgical patients in Tikur Anbessa Hospital, Addis Ababa, Ethiopia. Am J Infect Control (1988) 1.13
Some aspects of the relations between rheumatoid arthritis, antigamma-globulin factors and the polymorphism of human gamma globulin. Ann N Y Acad Sci (1965) 1.12
Etiology of pneumonia, sepsis and meningitis in infants younger than three months of age in Ethiopia. Pediatr Infect Dis J (1999) 1.12
Bioavailability of metronidazole in fasting and non-fasting healthy subjects and in patients with Crohn's disease. Eur J Clin Pharmacol (1977) 1.10
Binding of plasminogen to Neisseria meningitidis and Neisseria gonorrhoeae and formation of surface-associated plasmin. J Infect Dis (1992) 1.10
Comparative studies of antigen 21 in Mycobacterium and Nocardia species: possible taxonomic relationships with Mycobacterium leprae. Infect Immun (1980) 1.09
Capacity of group A, B, C, D, and G streptococci to agglutinate sensitized sheep red cells. Acta Pathol Microbiol Scand B Microbiol Immunol (1974) 1.09
Immunoglobulin-binding structure on bovine group G streptococci different from type III Fc receptors on human group G streptococci. Infect Immun (1979) 1.08
Chemotaxis of polymorphonuclear leukocytes by protein A of the staphylococcus. Proc Soc Exp Biol Med (1970) 1.07
Ligand-binding sites for streptolysin O and staphylococcal protein A on different parts of the same myeloma globulin. Acta Pathol Microbiol Scand (1967) 1.07
Evaluation of spiramycin as a therapeutic agent for elimination of nasopharyngeal pathogens. Possible use of spiramycin for middle ear infections and for gonococcal and meningococcal nasopharyngeal carriage. Scand J Infect Dis (1978) 1.06
Protein A in Staphylococcus aureus strains of human and bovine origin. Acta Pathol Microbiol Scand B Microbiol Immunol (1972) 1.06
New receptor for human plasminogen on gram positive cocci. APMIS (1989) 1.06
Wild-type distributions of seven oral second-line drugs against Mycobacterium tuberculosis. Int J Tuberc Lung Dis (2011) 1.06
Diversity among 2481 Escherichia coli from women with community-acquired lower urinary tract infections in 17 countries. J Antimicrob Chemother (2005) 1.03
Interaction of streptococci with the Fc fragment of IgG. Acta Pathol Microbiol Scand C (1976) 1.02
Hospital-acquired infections among obstetric and gynaecological patients at Tikur Anbessa Hospital, Addis Ababa. J Hosp Infect (1988) 1.01
Isoelectric points and surface hydrophobicity of Gram-positive cocci as determined by cross-partition and hydrophobic affinity partition in aqueous two-phase systems. Infect Immun (1982) 1.01
Streptokinase activity among group A streptococci in relation to streptokinase genotype, plasminogen binding, and disease manifestations. Microb Pathog (1995) 1.00
Interactions between human serum proteins and oral streptococci reveal occurrence of receptors for aggregated beta 2-microglobulin. Infect Immun (1979) 1.00
A one-year study of streptococcal infections and their complications among Ethiopian children. Epidemiol Infect (1992) 1.00
The bacteriology of nosocomial infections at Tikur Anbessa Teaching Hospital, Addis Ababa. Acta Pathol Microbiol Immunol Scand B (1987) 1.00
Staphylococcus aureus resistant to fusidic acid among Swedish children: a follow-up study. Scand J Infect Dis (2006) 0.99
Tetracycline-resistant group A streptococci and pneumococci. Scand J Infect Dis (1972) 0.99
Analysis of a single reference strain for determination of gentamicin regression line constants and inhibition zone diameter breakpoints in quality control of disk diffusion antibiotic susceptibility testing. J Clin Microbiol (1982) 0.99
Cell mediated and humoral immunity in "reversal reactions". Int J Lepr Other Mycobact Dis (1976) 0.99
Antimicrobial susceptibility in Escherichia coli of human and avian origin--a comparison of wild-type distributions. Clin Microbiol Infect (2009) 0.99
Immunochemical aspects of Fc-medicated binding of human IgG subclasses to group A, C and G streptococci. Mol Immunol (1980) 0.98
Purification of staphylococcal protein A using immunosorbents. Scand J Immunol (1973) 0.98
Solid-phase radioimmunoassay of immunoglobulin G antibodies to Staphylococcus aureus peptidoglycan in patients with staphylococcal infections. Acta Pathol Microbiol Immunol Scand B (1983) 0.97
Surface bound plasmin promotes migration of Streptococcus pneumoniae through reconstituted basement membranes. Microb Pathog (1999) 0.96
Demonstration of a receptor for mouse and human serum albumin in Streptococcus pyogenes. Acta Pathol Microbiol Immunol Scand B (1983) 0.95